LB-P6

N/A

Report date: 2024/12/31 16:09:17

Base Information

Drug NameLB-P6
Drug Alias NameLB-P6
ClassificationBiologics > Live Biotherapeutic
Mechanisms of ActionBacteria replacementsMicrobiome modulators
TargetsNot applicable
Therapy Area/IndicationsAutoimmune DiseasesMetabolic Dysfunction-Associated Steatotic Liver DiseaseArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLISCure Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesLISCure Biosciences Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesMetabolic Dysfunction-Associated Steatotic Liver DiseaseArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A